SI1919951T1 - Anti-tnf-alfa protitelesa in postopki za uporabo - Google Patents
Anti-tnf-alfa protitelesa in postopki za uporaboInfo
- Publication number
- SI1919951T1 SI1919951T1 SI200631917T SI200631917T SI1919951T1 SI 1919951 T1 SI1919951 T1 SI 1919951T1 SI 200631917 T SI200631917 T SI 200631917T SI 200631917 T SI200631917 T SI 200631917T SI 1919951 T1 SI1919951 T1 SI 1919951T1
- Authority
- SI
- Slovenia
- Prior art keywords
- tnf
- methods
- alpha antibodies
- antibodies
- alpha
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70542705P | 2005-08-04 | 2005-08-04 | |
| PCT/US2006/029114 WO2007019064A2 (en) | 2005-08-04 | 2006-07-27 | ANTI-TNFα ANTIBODIES AND METHODS OF USE |
| EP06774701.4A EP1919951B1 (en) | 2005-08-04 | 2006-07-27 | Anti-tnf-alpha antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1919951T1 true SI1919951T1 (sl) | 2015-05-29 |
Family
ID=37727836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200631917T SI1919951T1 (sl) | 2005-08-04 | 2006-07-27 | Anti-tnf-alfa protitelesa in postopki za uporabo |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7560108B2 (sl) |
| EP (1) | EP1919951B1 (sl) |
| JP (2) | JP2009502195A (sl) |
| DK (1) | DK1919951T3 (sl) |
| ES (1) | ES2535426T3 (sl) |
| PL (1) | PL1919951T3 (sl) |
| PT (1) | PT1919951E (sl) |
| SI (1) | SI1919951T1 (sl) |
| WO (1) | WO2007019064A2 (sl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7807168B2 (en) | 2007-04-10 | 2010-10-05 | Vaccinex, Inc. | Selection of human TNFα specific antibodies |
| CL2010000019A1 (es) * | 2010-01-11 | 2010-06-11 | Univ Chile | Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion. |
| US20140300477A1 (en) | 2012-09-25 | 2014-10-09 | Woodstream Corporation | Wireless notification systems and methods for electronic rodent traps |
| US20140085100A1 (en) | 2012-09-25 | 2014-03-27 | Woodstream Corporation | Wireless notification system and method for electronic rodent traps |
| AR118191A1 (es) * | 2019-02-28 | 2021-09-22 | Celltrion Inc | MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa |
| CN119264230A (zh) * | 2024-08-27 | 2025-01-07 | 湖南农业大学 | 一种猪流行性腹泻病毒s1重组蛋白、试剂盒及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1905782A1 (en) * | 1991-03-18 | 2008-04-02 | New York University | Monoclonal and chimeric antibodies specific for human tumor necrosis factor |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
| US5698195A (en) | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
| CU22615A1 (es) * | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| JP2002512624A (ja) * | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | 非免疫原性タンパク質の製造方法 |
| DK1015576T3 (da) | 1997-09-16 | 2005-08-29 | Egea Biosciences Llc | Fremgangsmåde til fuldstændig kemisk syntese og aggregering af gener og genomer |
| US6835550B1 (en) * | 1998-04-15 | 2004-12-28 | Genencor International, Inc. | Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins |
| ATE352559T1 (de) * | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
| ES2346517T3 (es) | 2001-11-12 | 2010-10-18 | Merck Patent Gmbh | Anticuerpo modificado anti-tnf alfa. |
| US20040131613A1 (en) * | 2003-01-08 | 2004-07-08 | Watkins Jeffry D. | TNF-alpha binding molecules |
| US7101978B2 (en) * | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
| US6832823B1 (en) * | 2003-05-30 | 2004-12-21 | Hewlett-Packard Development Company, L.P. | Disabling ink ejection elements to decrease dot placement artifacts in an inkjet printhead |
-
2006
- 2006-07-27 SI SI200631917T patent/SI1919951T1/sl unknown
- 2006-07-27 PT PT06774701T patent/PT1919951E/pt unknown
- 2006-07-27 PL PL06774701T patent/PL1919951T3/pl unknown
- 2006-07-27 ES ES06774701.4T patent/ES2535426T3/es active Active
- 2006-07-27 WO PCT/US2006/029114 patent/WO2007019064A2/en not_active Ceased
- 2006-07-27 DK DK06774701.4T patent/DK1919951T3/en active
- 2006-07-27 EP EP06774701.4A patent/EP1919951B1/en active Active
- 2006-07-27 JP JP2008525034A patent/JP2009502195A/ja active Pending
- 2006-07-31 US US11/496,129 patent/US7560108B2/en active Active
-
2008
- 2008-08-11 US US12/189,237 patent/US7790871B2/en active Active
-
2012
- 2012-09-18 JP JP2012204815A patent/JP5261602B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1919951A2 (en) | 2008-05-14 |
| US20090012266A1 (en) | 2009-01-08 |
| ES2535426T3 (es) | 2015-05-11 |
| HK1117849A1 (en) | 2009-01-23 |
| EP1919951B1 (en) | 2015-01-28 |
| US7560108B2 (en) | 2009-07-14 |
| US7790871B2 (en) | 2010-09-07 |
| JP2009502195A (ja) | 2009-01-29 |
| PL1919951T3 (pl) | 2015-07-31 |
| US20070092518A1 (en) | 2007-04-26 |
| EP1919951A4 (en) | 2011-01-19 |
| JP5261602B2 (ja) | 2013-08-14 |
| WO2007019064A3 (en) | 2009-04-16 |
| DK1919951T3 (en) | 2015-02-16 |
| WO2007019064A2 (en) | 2007-02-15 |
| JP2013034481A (ja) | 2013-02-21 |
| PT1919951E (pt) | 2015-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL192129A0 (en) | Anti-mn antibodies and methods of using same | |
| EP1868647A4 (en) | OV064 BINDING ANTIBODIES AND METHOD FOR THEIR USE | |
| IL178593A (en) | Specific antibodies of fcγriib and methods for their use | |
| IL272883A (en) | Monoclonal antibodies and their uses | |
| IL186659A0 (en) | Il-31 monoclonal antibodies and methods of use | |
| IL188748A0 (en) | Anti-cd26 antibodies and methods of use thereof | |
| SG10201606980VA (en) | Anti-cd3 antibodies and methods of use thereof | |
| IL191820A0 (en) | Anti-ox40l antibodies and methods using same | |
| SI2594586T1 (sl) | IL-31 monoklonska protitelesa in metode uporabe | |
| LT2029173T (lt) | Fc riib specifiniai antikūnai ir jų panaudojimo būdai | |
| IL179102A (en) | Human-specific fcγriib antibodies and methods for their use | |
| IL192419A0 (en) | Anti-ephb4 antibodies and methods using same | |
| IL187710A0 (en) | Anti-trkb monoclonal antibodies and uses thereof | |
| IL187375A0 (en) | Anti-gm-csf antibodies and uses therefor | |
| IL222922A (en) | Antibodies against neurophilin-1 and their use | |
| IL198020A0 (en) | Anti-cd20 antibodies and methods of use | |
| ZA200710496B (en) | Antibodies directed to CD20 and used thereof | |
| IL187303A0 (en) | Methods of prepering 3 - cyano - quinolines and intermediates made thereby | |
| IL182943A0 (en) | Ovr110 antibody compositions and methods of use | |
| PT2185719E (pt) | Anticorpos anti-rantes e processos para a sua utilização | |
| IL185309A0 (en) | Isoqunoline compounds and methods of use thereof | |
| IL231891A0 (en) | Anti-2ephriinb antibodies and methods of using them | |
| EP2077325A4 (en) | MONOCLONAL ANTIBODY AND ITS USE | |
| PL1919951T3 (pl) | Przeciwciała anty-TNF-alfa oraz ich zastosowania | |
| IL186277A0 (en) | Dnt-maleate and methods of preparation thereof |